Skip to main content
Top
Published in: Ophthalmology and Therapy 5/2023

Open Access 06-07-2023 | Macular Degeneration | REVIEW

Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials

Authors: Helene O. Larsen, Jakob Grauslund, Anna S. Vergmann

Published in: Ophthalmology and Therapy | Issue 5/2023

Login to get access

Abstract

Introduction

This review aims to assess the efficacy, durability and safety of faricimab—a dual vascular endothelial growth factor and angiopoietin 2 inhibitor—in patients with neovascular age-related macular degeneration (nAMD) and diabetic macula oedema (DMO). It summarises the findings of current studies on faricimab and discusses whether this new drug may fill a gap in current treatment options.

Methods

We performed a search of the PubMed, Cochrane, Web of Science and EMBASE databases for publications on faricimab between 29 November 2022 and 10 May 2023, and a search of ClinicalTrials.gov for the protocols on clinical trials for this review. We included clinical trials, case–control studies and observational studies.

Results

In phase 3 trials of nAMD, the efficacy of faricimab was non-inferior to aflibercept (+ 5.8–6.6 vs. + 5.1–6.6 Early Treatment Diabetic Retinopathy Study [ETDRS] letters). At study end, 80% of faricimab-treated patients were on ≥ 12-week dosing intervals, and 44.9–45.7% of faricimab-treated patients were on 16-week dosing intervals. Total adverse events, as well as serious ocular adverse events, were comparable between groups. In phase 3 trials of DMO, efficacy of faricimab was non-inferior to aflibercept (+ 10.7–11.8 vs. + 10.3–10.9 ETDRS letters). At study end, > 70% of patients in the personalised treatment interval faricimab group were on ≥ 12-week dosing intervals, and 51–53% were on 16-week dosing intervals. Total adverse events were comparable between groups, although the rate of serious ocular adverse events was higher in the faricimab groups than in the aflibercept groups (1.9–3.1% vs. 0.6–1.9%, respectively). In real-world studies of treatment-resistant nAMD or DMO, faricimab demonstrated superior efficacy compared to aflibercept. In a real-world study of mostly previously treated nAMD, faricimab demonstrated some efficacy.

Conclusion

Faricimab demonstrated non-inferior to superior efficacy, strong durability and acceptable safety in treatment-naïve nAMD and mostly treatment-naïve DMO, as well as superior efficacy in treatment-resistant nAMD and DMO. However, further research is needed on faricimab in real-world settings.
Literature
1.
go back to reference Wang Y, Zhong Y, Zhang L, et al. Global incidence, progression, and risk factors of age-related macular degeneration and projection of disease statistics in 30 years: a modeling study. Gerontology. 2022;68:721–35.CrossRefPubMed Wang Y, Zhong Y, Zhang L, et al. Global incidence, progression, and risk factors of age-related macular degeneration and projection of disease statistics in 30 years: a modeling study. Gerontology. 2022;68:721–35.CrossRefPubMed
2.
go back to reference Thomas CJ, Mirza RG, Gill MK. Age-related macular degeneration. Med Clin. 2021;105:473–91. Thomas CJ, Mirza RG, Gill MK. Age-related macular degeneration. Med Clin. 2021;105:473–91.
4.
go back to reference Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RP. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol. 2020;104:1077–84.CrossRefPubMed Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RP. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol. 2020;104:1077–84.CrossRefPubMed
6.
go back to reference Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021;35:1305–16.CrossRefPubMedPubMedCentral Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021;35:1305–16.CrossRefPubMedPubMedCentral
7.
go back to reference Heier JS, Khanani AM, Ruiz CQ, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40.CrossRefPubMed Heier JS, Khanani AM, Ruiz CQ, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40.CrossRefPubMed
8.
go back to reference Zhang J, Zhang J, Zhang C, et al. Diabetic macular edema: current understanding. Molecular mechanisms and therapeutic implications. Cells. 2022;11:3362.CrossRefPubMedPubMedCentral Zhang J, Zhang J, Zhang C, et al. Diabetic macular edema: current understanding. Molecular mechanisms and therapeutic implications. Cells. 2022;11:3362.CrossRefPubMedPubMedCentral
9.
go back to reference Lin K-Y, Hsih W-H, Lin Y-B, Wen C-Y, Chang T-J. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig. 2021;12:1322–5.CrossRefPubMedPubMedCentral Lin K-Y, Hsih W-H, Lin Y-B, Wen C-Y, Chang T-J. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig. 2021;12:1322–5.CrossRefPubMedPubMedCentral
11.
go back to reference Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28,658 patient eyes. Br J Ophthalmol. 2021;105:216–21.CrossRefPubMed Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28,658 patient eyes. Br J Ophthalmol. 2021;105:216–21.CrossRefPubMed
12.
go back to reference Van Aken E, Favreau M, Ramboer E, et al. Real-world outcomes in patients with diabetic macular edema treated long term with ranibizumab (VISION study). Clin Ophthalmol. 2020;14:4173–85.CrossRefPubMedPubMedCentral Van Aken E, Favreau M, Ramboer E, et al. Real-world outcomes in patients with diabetic macular edema treated long term with ranibizumab (VISION study). Clin Ophthalmol. 2020;14:4173–85.CrossRefPubMedPubMedCentral
13.
go back to reference Glassman AR, Wells JA, Josic K, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (protocol t extension study). Ophthalmology. 2020;127:1201–10.CrossRefPubMed Glassman AR, Wells JA, Josic K, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (protocol t extension study). Ophthalmology. 2020;127:1201–10.CrossRefPubMed
14.
go back to reference Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220–6.CrossRefPubMed Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220–6.CrossRefPubMed
15.
go back to reference Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes. Ophthalmol Retina. 2020;4:19–30.CrossRefPubMed Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes. Ophthalmol Retina. 2020;4:19–30.CrossRefPubMed
16.
go back to reference Khanani AM, Skelly A, Bezlyak V, et al. SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2020;4:122–33.CrossRefPubMed Khanani AM, Skelly A, Bezlyak V, et al. SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2020;4:122–33.CrossRefPubMed
17.
go back to reference Chia MA, Keane PA. Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease? Lancet. 2022;399:697–9.CrossRefPubMed Chia MA, Keane PA. Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease? Lancet. 2022;399:697–9.CrossRefPubMed
18.
go back to reference Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128:234–47.CrossRefPubMed Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128:234–47.CrossRefPubMed
21.
go back to reference Sahni J, Dugel PU, Patel SS, et al. Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138:955–63.CrossRefPubMed Sahni J, Dugel PU, Patel SS, et al. Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138:955–63.CrossRefPubMed
22.
go back to reference Khanani AM, Patel SS, Ferrone PJ, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138:964–72.CrossRefPubMedPubMedCentral Khanani AM, Patel SS, Ferrone PJ, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138:964–72.CrossRefPubMedPubMedCentral
23.
25.
go back to reference Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126:1155–70.CrossRefPubMed Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126:1155–70.CrossRefPubMed
26.
go back to reference Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741–55.CrossRefPubMed Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741–55.CrossRefPubMed
28.
go back to reference Nguyen QD, Heier JS, Do DV, et al. The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. Int J Retina Vitr. 2020;6:48.CrossRef Nguyen QD, Heier JS, Do DV, et al. The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. Int J Retina Vitr. 2020;6:48.CrossRef
29.
go back to reference Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Faricimab: expanding horizon beyond VEGF. Eye (London). 2020;34:802–4.CrossRef Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Faricimab: expanding horizon beyond VEGF. Eye (London). 2020;34:802–4.CrossRef
30.
go back to reference Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–608.CrossRefPubMed Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–608.CrossRefPubMed
33.
go back to reference Sharma A, Nilesh K, Parachuri N, et al. Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials. Eye (London). 2022;36:679–80.CrossRef Sharma A, Nilesh K, Parachuri N, et al. Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials. Eye (London). 2022;36:679–80.CrossRef
34.
go back to reference Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post Hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1050–9.CrossRefPubMed Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post Hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1050–9.CrossRefPubMed
36.
go back to reference Sen P, Manayath G, Shroff D, Salloju V, Dhar P. Polypoidal choroidal vasculopathy: an update on diagnosis and treatment. Clin Ophthalmol. 2023;17:53–70.CrossRefPubMedPubMedCentral Sen P, Manayath G, Shroff D, Salloju V, Dhar P. Polypoidal choroidal vasculopathy: an update on diagnosis and treatment. Clin Ophthalmol. 2023;17:53–70.CrossRefPubMedPubMedCentral
37.
go back to reference Fenner BJ, Cheung CMG, Sim SS, et al. Evolving treatment paradigms for PCV. Eye (London). 2022;36:257–65.CrossRef Fenner BJ, Cheung CMG, Sim SS, et al. Evolving treatment paradigms for PCV. Eye (London). 2022;36:257–65.CrossRef
38.
go back to reference Lee WK, Lai T, Iida T, Chen S-J, Cheung G, Margaron P. Design and Rationale of the SALWEEN Trial: A Phase 3b/4 Study of Faricimab, a Dual Angiopoietin-2 and Vascular Endothelial Growth Factor-A Inhibitor, in Patients With Polypoidal Choroidal Vasculopathy. https://2022.apvrs.org/abstract/. Lee WK, Lai T, Iida T, Chen S-J, Cheung G, Margaron P. Design and Rationale of the SALWEEN Trial: A Phase 3b/4 Study of Faricimab, a Dual Angiopoietin-2 and Vascular Endothelial Growth Factor-A Inhibitor, in Patients With Polypoidal Choroidal Vasculopathy. https://​2022.​apvrs.​org/​abstract/​.
39.
go back to reference Bobadilla M, Pariente A, Oca AI, Peláez R, Pérez-Sala Á, Larráyoz M. Biomarkers as predictive factors of anti-VEGF response. Biomedicines. 2022;10:1003.CrossRefPubMedPubMedCentral Bobadilla M, Pariente A, Oca AI, Peláez R, Pérez-Sala Á, Larráyoz M. Biomarkers as predictive factors of anti-VEGF response. Biomedicines. 2022;10:1003.CrossRefPubMedPubMedCentral
40.
go back to reference Diack C, Schwab D, Cosson V, Buchheit V, Mazer N, Frey N. A baseline score to predict response to ranibizumab treatment in neovascular age-related macular degeneration. Transl Vis Sci Technol. 2021;10:11.CrossRefPubMedPubMedCentral Diack C, Schwab D, Cosson V, Buchheit V, Mazer N, Frey N. A baseline score to predict response to ranibizumab treatment in neovascular age-related macular degeneration. Transl Vis Sci Technol. 2021;10:11.CrossRefPubMedPubMedCentral
Metadata
Title
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
Authors
Helene O. Larsen
Jakob Grauslund
Anna S. Vergmann
Publication date
06-07-2023
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy / Issue 5/2023
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-023-00753-6

Other articles of this Issue 5/2023

Ophthalmology and Therapy 5/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare